Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children

JAMA

Volumn 309, Issue 23, 2013, Pages 2473-2479

  Ziegler, Anette G ^a   Rewers, Marian ^b   Simell, Olli ^c,d   Simell, Tuula ^c,d   Lempainen, Johanna ^c,d   Steck, Andrea ^b   Winkler, Christiane ^a   Ilonen, Jorma ^c,e   Veijola, Riitta ^f   Knip, Mikael ^g,h   Bonifacio, Ezio ⁱ   Eisenbarth, George S ^b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TURKU   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY OF EASTERN FINLAND   (Finland)

^f UNIVERSITY OF OULU   (Finland)

^g UNIVERSITY OF HELSINKI   (Finland)

^h TAMPERE UNIVERSITY HOSPITAL   (Finland)

ⁱ DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; AUTOANTIBODY; GLUTAMIC ACID CARBOXYLASE 65 AUTOANTIBODY; INSULIN ANTIBODY; INSULINOMA ANTIGEN 2; ISLET AUTOANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ANTIBODY DETECTION; ARTICLE; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FINLAND; FOLLOW UP; GENOTYPE; GERMANY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEROCONVERSION; SEX DIFFERENCE; UNITED STATES;

EID: 84879114358     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.6285     Document Type: Article

References (26)

1. Eisenbarth GS. Type I diabetes mellitus: a chronic autoimmune disease. N Engl J Med. 1986;314(21):1360-1368. (Pubitemid 16122469)
2. Milton B, Holland P, Whitehead M. The social and economic consequences of childhood-onset type 1 diabetes mellitus across the lifecourse: a systematic review. Diabet Med. 2006;23(8):821-829. (Pubitemid 44141068)
3. Tarn AC, Thomas JM, Dean BM, et al. Predicting insulin-dependent diabetes. Lancet. 1988;1(8590):845-850. (Pubitemid 18092401)
4. Gale EA, Bingley PJ, Emmett CL, Collier T; European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet. 2004;363(9413):925-931.
5. Diabetes Prevention Trial - Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002;346(22):1685-1691.
6. Vehik K, Cuthbertson D, Ruhlig H, Schatz DA, Peakman M, Krischer JP; DPT-1 and TrialNet Study Groups. Long-term outcome of individuals treated with oral insulin: diabetes prevention trial-type 1 (DPT-1) oral insulin trial. Diabetes Care. 2011;34(7):1585-1590.
7. Näntö-Salonen K, Kupila A, Simell S, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet. 2008;372(9651):1746-1755.
8. Rewers M, Bugawan TL, Norris JM, et al. Newborn screening for HLA markers associated with IDDM: Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia. 1996;39(7):807-812. (Pubitemid 26228110)
9. Ziegler AG, Hummel M, Schenker M, Bonifacio E. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB study. Diabetes. 1999;48(3):460-468. (Pubitemid 29106857)
10. Hummel S, Pflüger M, Hummel M, Bonifacio E, Ziegler AG. Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study. Diabetes Care. 2011;34(6):1301-1305.
11. Kukko M, Kimpimäki T, Korhonen S, et al. Dynamics of diabetes-associated autoantibodies in young children with human leukocyte antigen-conferred risk of type 1 diabetes recruited from the general population. J Clin Endocrinol Metab. 2005;90(5):2712-2717. (Pubitemid 40686314)
12. Yu L, Rewers M, Gianani R, et al. Antiislet autoantibodies usually develop sequentially rather than simultaneously. J Clin Endocrinol Metab. 1996;81(12):4264-4267. (Pubitemid 26412027)
13. Achenbach P, Lampasona V, Landherr U, et al. Autoantibodies to zinc transporter 8 and SLC30A8 genotype stratify type 1 diabetes risk. Diabetologia. 2009;52(9):1881-1888.
14. Puavilai G, Chanprasertyotin S, Sriphrapradaeng A; World Health Organization. Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO consultation criteria, and 1985 WHO criteria. Diabetes Res Clin Pract. 1999;44(1):21-26. (Pubitemid 29446185)
15. Knip M, Korhonen S, Kulmala P, et al. Prediction of type 1 diabetes in the general population. Diabetes Care. 2010;33(6):1206-1212.
16. Hummel M, Bonifacio E, Schmid S, Walter M, Knopff A, Ziegler AG. Brief communication: early appearance of islet autoantibodies predicts childhood type 1 diabetes in offspring of diabetic parents. Ann Intern Med. 2004;140(11):882-886.
17. Bingley PJ, Gale EA; European Nicotinamide Diabetes Intervention Trial (ENDIT) Group. Progression to type 1 diabetes in islet cell antibody-positive relatives in the European Nicotinamide Diabetes Intervention Trial: the role of additional immune, genetic and metabolic markers of risk. Diabetologia. 2006;49(5):881-890.
18. Yu L, Boulware DC, Beam CA, et al; Type 1 Diabetes TrialNet Study Group. Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. Diabetes Care. 2012;35(6):1213-1218.
19. Orban T, Sosenko JM, Cuthbertson D, et al; Diabetes Prevention Trial-Type 1 Study Group. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care. 2009;32(12):2269-2274.
20. Achenbach P, Warncke K, Reiter J, et al. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes. 2004;53(2):384-392. (Pubitemid 38174554)
21. Decochez K, Truyen I, van der Auwera B, et al Belgian Diabetes Registry. Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes. Diabetologia. 2005;48(4):687-694. (Pubitemid 40591224)
22. Koczwara K, Bonifacio E, Ziegler AG. Transmission of maternal islet antibodies and risk of autoimmune diabetes in offspring of mothers with type 1 diabetes. Diabetes. 2004;53(1):1-4. (Pubitemid 38044690)
23. Vives M, Somoza N, Soldevila G, et al. Reevaluation of autoantibodies to islet cell membrane in IDDM: failure to detect islet cell surface antibodies using human islet cells as substrate. Diabetes. 1992;41(12):1624-1631.
24. Bonifacio E, Bingley PJ, Shattock M, et al. Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes. Lancet. 1990;335(8682):147-149. (Pubitemid 20032735)
25. Bonifacio E, Lampasona V, Bingley PJ. IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes-associated tyrosine phosphatase autoantigens. J Immunol. 1998;161(5):2648-2654. (Pubitemid 28397086)
26. Colman PG, Steele C, Couper JJ, et al. Islet autoimmunity in infants with a type I diabetic relative is common but is frequently restricted to one autoantibody. Diabetologia. 2000;43(2):203-209. (Pubitemid 30126825)